Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Sheba Medical Center.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Dr. Daniel Silverberg, Sheba Medical Center Identifier:
First received: August 19, 2012
Last updated: NA
Last verified: August 2012
History: No changes posted

Abdominal aortic aneurysm (AAA) is a common disease that develops from degeneration of the aortic wall. The natural history of AAA is gradual expansion and if left untreated may result in rupture and death. The mechanism of the development of this disease is unknown however it appears to be multifactorial and possibly related to degradation processes within the arterial wall. There is growing evidence that Angiotensin receptor blockers ( ARBS) may have an inhibitory effect on remodelling processes within the arterial wall, thus inhibiting degeneration of the vessel wall.

Study hypothesis: ARBS are associated with smaller diameters of aortas among hypertensive patients, and are associated with a lower rate of aortic expansion compared to other antihypertensive drugs.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Estimated Enrollment: 150
Study Start Date: May 2011
Hypertensive patients treated with ARBs
ACE inhibitors
Hypertensive patients treated with ACE inhibitors
Hypertensive patients treated with non ARBs or ACE inhibitors meds


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
medically treated hypertensive patients, ages 50-80

Inclusion Criteria:

  • medically treated hypertensive patients, ages 50-80

Exclusion Criteria:

  • pregnant women
  • patients previously treated for aortic disease
  • unable to sign informed consent, minors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01670903

Contact: Daniel Silverberg, MD 035302712

Sheba Medical Center Recruiting
Tel Hashomer, Israel
Sub-Investigator: Jacob Schneiderman, MD         
Sub-Investigator: Ehud Grossman, MD         
Sub-Investigator: Moshe Halak, MD         
Sub-Investigator: Anan Younes, MD         
Sub-Investigator: Dmitry Yakubovitz, MD         
Sub-Investigator: Bashir Sheik-yosef, MD         
Sub-Investigator: Ronnie E Reinitz, MD         
Sheba Medical Center Recruiting
Tel Hashomer, Israel
Contact: Daniel Silverberg, MD   
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Daniel Silverberg, MD Sheba Medical Center
  More Information

Responsible Party: Dr. Daniel Silverberg, Senior consultant - Vascular surgery, Sheba Medical Center Identifier: NCT01670903     History of Changes
Other Study ID Numbers: SHEBA-12-8336-DS-CTIL
Study First Received: August 19, 2012
Last Updated: August 19, 2012

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Angiotensin II
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II Type 1 Receptor Blockers
Vasoconstrictor Agents
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiotensin Receptor Antagonists processed this record on April 28, 2017